U.S. Markets close in 1 hr 53 mins
  • S&P 500

    3,840.23
    +8.84 (+0.23%)
     
  • Dow 30

    30,979.03
    +11.21 (+0.04%)
     
  • Nasdaq

    11,362.56
    +40.32 (+0.36%)
     
  • Russell 2000

    1,724.21
    -17.12 (-0.98%)
     
  • Crude Oil

    98.00
    -1.50 (-1.51%)
     
  • Gold

    1,733.90
    -30.00 (-1.70%)
     
  • Silver

    19.08
    -0.04 (-0.19%)
     
  • EUR/USD

    1.0192
    -0.0079 (-0.7644%)
     
  • 10-Yr Bond

    2.9020
    +0.0930 (+3.31%)
     
  • Vix

    27.35
    -0.19 (-0.69%)
     
  • GBP/USD

    1.1937
    -0.0015 (-0.1265%)
     
  • USD/JPY

    135.6680
    -0.1740 (-0.1281%)
     
  • BTC-USD

    20,222.42
    +504.18 (+2.56%)
     
  • CMC Crypto 200

    438.28
    +2.76 (+0.63%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

908 Devices to Report First Quarter Financial Results on May 10, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, April 12, 2022--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

Source: 908 Devices Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005444/en/

Contacts

Investor Contact
Carrie Mendivil
IR@908devices.com